PT - JOURNAL ARTICLE AU - Jaiswal, Vikash AU - Alquraish, Danah AU - Nagpal, Shavy AU - Mukherjee, Dattatreya AU - Shrestha, Prakriti Singh AU - Velazco, Diana Sanchez AU - Guntipalli, Prathima AU - Bhatnagar, Arushee AU - Savani, Saloni AU - Halilaj, Eldamhalji AU - Ruxmohan, Samir TI - INFLUENCE OF NOVEL CORONAVIRUS DISEASE (COVID-19) ON PARKINSON’S DISEASE: SYSTEMATIC REVIEW AID - 10.1101/2021.05.09.21256929 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.09.21256929 4099 - http://medrxiv.org/content/early/2021/05/12/2021.05.09.21256929.short 4100 - http://medrxiv.org/content/early/2021/05/12/2021.05.09.21256929.full AB - Background The novel Coronavirus (COVID-19) infection has affected the population with various medical issues including the underlying neurological comorbidities such as Parkinson disease. COVID – 19 is found to bind with the host angiotensin-converting enzyme 2 (ACE2) receptors for viral entry. ACE2 receptors are normally expressed in various body surfaces as well as in the neurons and glial cells where they act as an entry port to SARS-CoV-2 infection to invade the central nervous system (CNS). ACE2 are also highly expressed in dopamine neurons which might worsen the outcome in terms of motor symptoms in PD with the treatment course. It may lead to an indirect response via immune-mediated cytokine storms and propagate through CNS leading to damage. Parkinson’s disease has also been noticed due to certain post-viral infections apart from COVID-19 such as, HSV, Influenza virus A, Measles virus, Cytomegalovirus and Mumps (Olsen et al, 2018). We aim to provide a thorough review on neurological outcomes and impact of COVID-19 in Parkinson disease.Methods A systematic review was conducted to analyze the impact of COVID-19 in patients with Parkinson disease (> 21 yo). Systematic literature search was done using PubMed, Science Direct, Google Scholar and Cochrane databases. PRISMA guidelines were followed summarized in Fig. 3 for study acquisition.Results Of the Parkinson’s patients that were tested positive for SARS-CoV-2, worsening of motor symptoms were reported along with other COVID-19 symptoms (Fig. 4 and 5). These symptoms include bradykinesia, tremors, gait disturbances, delirium and dementia and severe spasms of arms and legs. Encephalopathy was also one of the main symptoms presented in two of the studies. Increased mortality rates were identified for those who were hospitalized due to COVID-19 and PD when compared to other patients.Conclusion Parkinson’s disease may experience substantial worsening of motor and non -motor symptoms during COVID 19. Due to the novelty of the virus, studies were reported from recent years and further extensive studies are needed to explore more about the disease severity and neurological outcomes when compared to other non-PD patients. Authors identify this as a limitation for this paper. Additional studies are needed to understand the role of ACE2 in increasing vulnerability to viruses and role of ACE inhibitors as treatment modality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTHIS PROJECT/PAPER IS NOT FUNDEDAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:THIS IS A SYSTEMIC REVIEW SO ETHICAL APPROVAL IS NOT NEEDEDAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesALL THE DATA ARE FULLY AVAILABLE IN THE MANUSCRIPT